Focus Partners Wealth
WST icon

Focus Partners Wealth’s West Pharmaceutical WST Stock Holding History

Focus Partners Wealth’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.87M Buy
13,557
+3,940
+41% +$1.2M 0.01% 974
2026
Q1 		$2.44M Sell
9,617
-355
-4% -$88.3K ﹤0.01% 1229
2025
Q4 		$2.74M Buy
9,972
+4,585
+85% +$1.25M ﹤0.01% 1188
2025
Q3 		$1.41M Buy
5,387
+687
+15% +$167K ﹤0.01% 1149
2025
Q2 		$1.03M Buy
4,700
+148
+3% +$31.6K ﹤0.01% 1129
2025
Q1 		$1.02M Sell
4,552
-534
-10% -$147K ﹤0.01% 1066
2024
Q4 		$1.67M Buy
5,086
+248
+5% +$78K ﹤0.01% 894
2024
Q3 		$1.45M Sell
4,838
-4,566
-49% -$1.4M ﹤0.01% 852
2024
Q2 		$3.1M Buy
9,404
+8,641
+1,133% +$3.05M 0.01% 584
2024
Q1 		$302K Buy
+763
New +$282K ﹤0.01% 832

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Focus Partners Wealth's WST Position: Q2 2026 in Review

Focus Partners Wealth increased its West Pharmaceutical (WST) stake by 41% in Q2 2026, buying an estimated $1.2M and bringing the position to 13,557 shares worth $4.87M. The position accounts for 0.01% of the portfolio, ranked #974.

Focus Partners Wealth first reported a position in WST in Q1 2024 and has held it in 10 quarters since. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Focus Partners Wealth held 13,557 shares of West Pharmaceutical worth $4.87M as of Q2 2026.
  • Focus Partners Wealth bought 3,940 West Pharmaceutical shares in Q2 2026, an estimated $1.2M.
  • West Pharmaceutical made up 0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #974 holding.
  • Focus Partners Wealth first reported a position in West Pharmaceutical in Q1 2024 and has held it in 10 quarters since.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.